A run-in phase clinical study for intravesical administration of durvalumab in patients with high-risk, non-muscle-invasive bladder cancer (NMIBC)

by A. Papatsoris, C. Fragkoulis, E. Fragkiadis, A. Pinitas, K. Tzannis, N. Gavalas, K. Stravodimos, K. Ntoumas, D. Mitropoulos, K. Constantinides, E. Giannopoulou, A. Bamias, C. Deliveliotis
Published 2020-07-01

Axitinib as a third or further line of treatment in renal cancer: a single institution experience

by G. Tsironis, M. Liontos, A. Kyriazoglou, K. Koutsoukos, A. Tsiara, M. Kaparelou, R. Zakopoulou, A. Cohen, E. Skafida, S. Fontara, F. Zagouri, A. Bamias, M. A. Dimopoulos
Published 2020-06-01

A subgroup analysis from the IMvigor130 study in patients with upper tract vs. lower tract locally advanced or metastatic urothelial carcinoma treated with atezolizumab plus platin...

by A. Bamias, M. De Santis, E. Grande, M. Marina, J-R. Li, J. Puente, K. Izumi, J.L. Lee, F. Kose, I. Antonyan, B. Ding, H. Patel, I. Davis
Published 2020-11-01